Moderate excess of pyruvate augments osteoclastogenesis

Jenna E. Fong1,*, Damien Le Nihouannen1,4, Kerstin Tiedemann1,2, Gulzhakhan Sadvakassova1,2, Jake E. Barralet1 and Svetlana V. Komarova2,1,§

1Faculty of Dentistry, McGill University, Montreal, QC H3A 1A4, Canada
2Shriners Hospital for Children – Canada, Montreal, QC H3G 1A6, Canada
*These authors contributed equally to this work
1Present address: INSERM U1026, BioTis – Tissue Engineering, Université Victor Segalen Bordeaux 2, Zone Nord, Bâtiment 4A – case postale 45, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France
§Author for correspondence (svetlana.komarova@mcgill.ca)

Introduction
Diabetes mellitus is a widespread group of metabolic diseases characterized by high blood glucose levels (Wild et al., 2004). Complications of diabetes affect many organs including bone, where diabetes is associated with changes in bone mineral density (Nicolucci and Folsom, 2001), an increased fracture risk (Khazai et al., 2009), and a delayed fracture repair (Kayal et al., 2007). These problems are most pronounced in hyperglycemic patients, but are mostly relieved if glucose is well controlled.

Summary
Cell differentiation leads to adaptive changes in energy metabolism. Conversely, hyperglycemia induces malfunction of many body systems, including bone, suggesting that energy metabolism reciprocally affects cell differentiation. We investigated how the differentiation of bone-resorbing osteoclasts, large polykaryons formed through fusion and growth of cells of monocytic origin, is affected by excess of energy substrate pyruvate and how energy metabolism changes during osteoclast differentiation. Surprisingly, small increases in pyruvate (1–2 mM above basal levels) augmented osteoclastogenesis in vitro and in vivo, while larger increases were not effective in vitro. Osteoclast differentiation increased cell mitochondrial activity and ATP levels, which were further augmented in energy-rich conditions. Conversely, the inhibition of respiration significantly reduced osteoclast number and size.

AMP-activated protein kinase (AMPK) acts as a metabolic sensor, which is inhibited in energy-rich conditions. We found that osteoclast differentiation was associated with an increase in AMPK levels and a change in AMPK isoform composition. Increased osteoclast size induced by pyruvate (1 mM above basal levels) was prevented in the presence of AMPK activator 5-amino-4-imidazole carboxamide ribonucleotide (AICAR). In keeping, inhibition of AMPK using dorsomorphin or siRNA to AMPK increased osteoclast size in control cultures to the level observed in the presence of pyruvate. Thus, we have found that a moderate excess of pyruvate enhances osteoclastogenesis, and that AMPK acts to tailor osteoclastogenesis to a cell’s bioenergetics capacity.

© 2013. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0).

Key words: Hyperglycemia, Pyruvate, Osteoclastogenesis, ATP, AMPK
differentiation (Lee et al., 2010), but relationship between osteoclast bioenergetics and metabolic sensors has not been addressed.

The aim of this study was to explore the interaction between homeostatic and functional signaling in osteoclasts in the presence of excessive amounts of pyruvate. To assess osteoclastogenesis in vitro, we differentiated osteoclasts from mouse bone marrow cells and from mouse monocytic RAW 264.7 cell line. To confirm our findings in vivo, we used healthy mice injected with pyruvate. Surprisingly, we have found that independently of the model used and basal levels of energy substrates, moderate excess of pyruvate significantly augmented osteoclastogenesis.

**Results**

Excess of pyruvate augments osteoclastogenesis in vitro and in vivo

We first supplemented RAW 264.7 culture media with pyruvate (1 mM) and assessed osteoclastogenesis. We have found that addition of pyruvate significantly augmented the formation of giant osteoclast-like cells induced by RANKL (Fig. 1A).

Appearance of osteoclastic cells in pyruvate-treated cultures suggests changes in cell size as well as number. Using confocal microscopy (Fig. 1B), we confirmed that osteoclast height was not significantly different, 22.2±1.9 μm in control cultures and 23.7±2.9 μm in pyruvate-treated cultures, indicating that change in osteoclast planar area can be used as a measure of osteoclast size. Extended analysis of osteoclastic cells generated in the presence of pyruvate indicated significant increase in the number of giant cells formed in the presence of RANKL (Fig. 1C), in the osteoclast size as estimated by cell planar surface area, (Fig. 1D), in the number of nuclei per osteoclast-like cell (Fig. 1E) and the cell surface per nucleus (Fig. 1F). Addition of pyruvate significantly increased osteoclast numbers only when added at low concentrations, 1–2 mM, while higher concentrations, 3–4 mM were not effective (Fig. 1G). To assess if osteoclast-stimulatory effect was unique to addition of pyruvate, we used another Krebs cycle intermediate citrate, and demonstrated that it similarly and significantly increases osteoclastogenesis (Fig. 1H).

RAW 264.7 cells were originally established from a tumor induced by Abelson murine leukemia virus, and the standard culture medium for RAW 264.7 cells, DMEM, contains 25 mM glucose,

---

**Fig. 1. Osteoclast differentiation from RAW 264.7 cells is augmented by excess in pyruvate.** (A–F) RAW 264.7 cells were cultured in supplemented DMEM containing 25 mM basal glucose and treated with RANKL (50 ng/ml) for 4 days in the absence or presence of pyruvate (Py, 1 mM). (A) Representative images of osteoclasts generated in control cultures and in pyruvate-treated cultures. Scale bar: 100 μm applies to both images. (B) Confocal images of osteoclasts generated from RAW 264.7 cells in the absence or presence of pyruvate and stained with lipophilic membrane probe DiI. Scale bar: 20 μm applies to both images. (C) Average number of osteoclasts formed in control and pyruvate-treated cultures. (D) Average osteoclast surface area. (E) Average number of nuclei per osteoclast. (F) Average surface area per nucleus. For C–F, data are means ± s.e.m.; n=6 independent experiments. Statistical significance compared to control was assessed by paired t-test, *P<0.05; **P<0.01; ***P<0.001. (G) RAW 264.7 cells were cultured with RANKL (50 ng/ml) for 4 days without additions (untreated, dashed line) or in the presence of pyruvate (1–4 mM) and osteoclast numbers were assessed. Data are means ± s.e.m.; n=8 independent experiments; **P<0.01 was assessed by ANOVA for correlated samples followed by Tukey post-test. (H) RAW 264.7 cells were cultured with RANKL (50 ng/ml) for 4 days without additions (open bar) or in the presence of 1–2 mM of pyruvate (gray bars) or citrate (black bars) and osteoclast numbers were assessed. Data are means ± s.e.m.; n=3 independent experiments, **P<0.01 was assessed by ANOVA for correlated samples followed by Tukey post-test.
Therefore, we assessed if the observed effect of pyruvate on osteoclastogenesis may be limited to this cell line and culture conditions only. We added pyruvate (1 mM) to two types of primary osteoclastogenesis cultures: i) non-adherent mouse bone marrow cells (NaBMC) treated with RANKL (100 ng/ml) and M-CSF (50 ng/ml) for 4 days (NaBMC) without (Control) or with additional pyruvate (1 mM). Scale bar: 100 μm applies to all images. (B) Representative images of mouse bone marrow cells cultured in supplemented MEM containing 5 mM basal glucose with AA (50 μg/ml) and RANKL (50 ng/ml) for 4 days (BMC) without (Control) or with additional pyruvate (1 mM). (C) Average number of osteoclasts formed in control or pyruvate-treated NaBMC (black bars) and BMC (white bars) cultures. (D) Average osteoclast surface area. (E) Average number of nuclei per osteoclast. (F) Average surface area per nucleus. For C–F, data are means ± s.e.m.; n=3 independent experiments for NaBMC, n=4 for BMC. *P<0.05; **P<0.01 compared to samples cultured at standard conditions as assessed by paired t-test.

Fig. 2. Osteoclast differentiation from bone marrow cells is augmented by pyruvate. (A) Representative images of non-adherent bone marrow cells cultured in supplemented α-MEM containing 5 mM basal glucose and 1 mM basal pyruvate with RANKL (100 ng/ml) and M-CSF (50 ng/ml) for 4 days (NaBMC) without (Control) or with additional pyruvate (1 mM). Scale bar: 100 μm applies to all images. (B) Representative images of mouse bone marrow cells cultured in supplemented MEM containing 5 mM basal glucose with AA (50 μg/ml) and RANKL (50 ng/ml) for 4 days (BMC) without (Control) or with pyruvate (1 mM). (C) Average number of osteoclasts formed in control or pyruvate-treated NaBMC (black bars) and BMC (white bars) cultures. (D) Average osteoclast surface area. (E) Average number of nuclei per osteoclast. (F) Average surface area per nucleus. For C–F, data are means ± s.e.m.; n=3 independent experiments for NaBMC, n=4 for BMC. *P<0.05; **P<0.01 compared to samples cultured at standard conditions as assessed by paired t-test.

Fig. 3. Osteoclasts formed in the presence of pyruvate exhibit higher resorptive activity. (A–C) RAW 264.7 cells were plated on calcium phosphate resorbable substrates and cultured with or without pyruvate for 7 days (Fig. 3A). We have found that the presence of pyruvate resulted in significant increase in area of pits formed by resorption of individual osteoclastic cells (Fig. 3B), and the total area resorbed that reflects both the number and the size of individual pits (Fig. 3C), indicating an increase in resorptive activity of osteoclastic cells formed in energy-rich conditions. Similarly, in primary osteoclast cultures we have found that exposure to pyruvate significantly augmented expression of osteoclastic genes necessary for resorptive activity, proteases cathepsin K and MMP-9, as well as osteoclast marker gene calcitonin receptor (Fig. 3D).

To assess if pyruvate affects osteoclast functional activity, we performed an in vitro pit formation assay. RAW 264.7 cells were plated on calcium phosphate resorbable substrates and cultured with or without pyruvate for 7 days (Fig. 3A). We have found that the presence of pyruvate resulted in significant increase in area of pits formed by resorption of individual osteoclastic cells (Fig. 3B), and the total area resorbed that reflects both the number and the size of individual pits (Fig. 3C), indicating an increase in resorptive activity of osteoclastic cells formed in energy-rich conditions. Similarly, in primary osteoclast cultures we have found that exposure to pyruvate significantly augmented expression of osteoclastic genes necessary for resorptive activity, proteases cathepsin K and MMP-9, as well as osteoclast marker gene calcitonin receptor (Fig. 3D).

We next examined if small excess of pyruvate can affect osteoclastogenesis in vivo. We injected healthy mice with pyruvate (0.75 g/kg/day) for 7 days and examined multinucleated TRAP-positive osteoclasts in long bones (Fig. 4A). In healthy animals, such injections are known to lead to a short-term, 20–40 minutes, increase in blood levels of pyruvate (Fukushima et al., 2009). We analyzed the steady-state levels of pyruvate and glucose in vehicle- or pyruvate-injected mice. While, as expected in well-controlled healthy animals, we did not observe significant change in blood pyruvate levels (Fig. 4B), the levels of glucose were significantly lower in pyruvate-treated mice (Fig. 4C). We have found that mild excess in pyruvate did not affect osteoclast number (Fig. 4D), but significantly increased the osteoclast surface area/bone area (Fig. 4E), indicating the formation of larger osteoclasts.
Effects of excess pyruvate on osteoclast precursors

In vitro, pyruvate augmented osteoclast formation at all time points (Fig. 5A), and had qualitatively similar effects at different levels of RANKL (Fig. 5B). We examined if pyruvate affects osteoclast precursors, and found that both in untreated and RANKL-treated cultures, addition of pyruvate significantly increased the precursor cell density (Fig. 5C). This effect was due to decrease in the proportion of apoptotic precursors in the presence of pyruvate (Fig. 5D), while precursor proliferation was unaffected by pyruvate (Fig. 5E).

Pyruvate-induced increase in osteoclast metabolic activity is critical for regulation of cell growth

Since pyruvate was previously suggested to exhibit anti-oxidant properties (Bassenge et al., 2000; Mohanty et al., 2002), we first examined its effect on the osteoclast redox status. In keeping with our previous studies (Le Nihouannen et al., 2010), we have found that osteoclast differentiation resulted in a decrease in total glutathione and the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG). Addition of pyruvate did not affect the total glutathione content (Fig. 6A), and only slightly increased a GSH/GSSG ratio (Fig. 6B).

We next examined the effect of pyruvate on osteoclast energy metabolism. Treatment of RAW 264.7 with RANKL induced significant media acidification, which was dramatically increased in the presence of pyruvate (Fig. 7A). Lactate exhibited an overall trend to increase in the presence of pyruvate and RANKL.
concentrations of respiration inhibitor NaN$_3$. Treatment with NaN$_3$ significantly and dose-dependently reduced both the number and the size of osteoclastic cells formed in the presence pyruvate (Fig. 7G). Whereas cell numbers were reduced to levels obtained in cultures not treated with pyruvate, the effect of NaN$_3$ on osteoclast size was more profound, suppressing cell size to significantly lower levels.

**AMPK acts as a mediator of osteoclastogenic effects of pyruvate**

Since energy metabolism affects ATP levels, and AMP/ATP ratio in turn regulates AMPK, we next assessed its involvement in the pyruvate-induced osteoclastogenesis. First, we examined AMPK expression during osteoclastogenesis. AMPK consists of three subunits: AMPK$_{\alpha}$, $\beta$ and $\gamma$. Activation of AMPK by AMP does not involve phosphorylation. Nevertheless, the overall capacity of a catalytic subunit AMPK$_{\alpha}$ is regulated by phosphorylation. AMPK$\beta$ is a regulatory subunit, which does not appear to affect osteoclastogenesis (Quinn et al., 2010), and AMPK$\gamma$ contains the AMP binding site acting as a sensor for AMP. Osteoclastic differentiation resulted in a gradual increase in the expression of AMPK$\alpha$, and a decrease in AMPK$\beta$2 and AMPK$\gamma$3 (Fig. 8A). Using immunoblotting, we confirmed the increase in AMPK$\alpha$1 protein levels and increase in AMPK$\alpha$1 phosphorylation (Fig. 8B), indicating change in AMPK sensitivity and/or capacity during osteoclastogenesis.

We next used RNA interference to assess the role of AMPK in regulation of osteoclastogenesis (Fig. 8C–F). Using three different siRNA oligonucleotides for AMPK$\alpha_2$ and AMPK$\gamma$, we were able to reduce the protein levels of these targets to 30–40% of control (Fig. 8C,D). Downregulation of AMPK$\alpha_2$, which interferes with AMPK capacity, resulted in a trend toward reducing number of osteoclast-like cells and did not affect their size. In contrast, siRNAs for AMPK$\gamma$, which interfere with AMPK ability to interact with AMP, did not affect osteoclast number (Fig. 8E), but significantly increased osteoclast size (Fig. 8F). These data suggest that catalytic activity of AMPK$\alpha_2$ is important for osteoclastogenesis, while the AMP-sensing capacity of AMPK$\gamma$ plays a role in regulating osteoclast growth.

AMPK is activated in energy-deficient conditions, and inhibited in energy-rich conditions. We next assessed if activation of AMPK with 5-amino-4-imidazole carboxamide ribonucleotide (AICAR) will interfere with the effects of pyruvate. Treatment with AICAR did not affect the ability of pyruvate to increase number of osteoclast-like cells (Fig. 8G), but significantly decreased cell size (Fig. 8H) to the levels observed in control cultures. AICAR also significantly reduced osteoclast numbers in control cultures, indicating that AMPK is not fully activated in control conditions in our experiments, thus implying that the control conditions are not energy deprived.

AMPK is downregulated in energy-rich conditions; therefore pharmacological AMPK inhibition is anticipated to mimic the effects of pyruvate. We have found that inhibition of AMPK with low concentrations of dorsomorphin in control cultures had a minor effect on cell number (Fig. 8I), but strongly increased size of giant osteoclast-like cells (Fig. 8J), demonstrating an induction of osteoclast growth to the levels observed in pyruvate-treated cultures.

**Discussion**

In this study, we have manipulated energy metabolism in vitro and in vivo by altering pyruvate levels, and have demonstrated...
that small increases in pyruvate augment osteoclastogenesis, resulting in the formation of larger and often more osteoclasts. This effect was observed in all the models of osteoclastogenesis, independent of basal glucose and pyruvate levels in the media. Addition of pyruvate augmented mitochondrial respiration, resulting in a threefold increase in ATP levels, confirming the bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. We identified the role of metabolic sensor AMPK in regulating osteoclast formation in bioenergetic nature of the effect. Therefore, energy production in the cell is actively adjusted for changing demands, and is determined by the levels of energy consumption, rather than extracellular concentrations of metabolic substrates (Atkinson, 1968; Ataullakhanov and Vitvitsky, 2002). Thus, at any basal glucose and pyruvate levels, cellular rates of glycolysis and oxidative phosphorylation are adapted to energy demands due to precursor proliferation, growth and fusion, and osteoclast differentiation, fusion and growth. If energy metabolism cannot provide sufficient ATP to maintain all these processes, some of them will not be accomplished (as we observed in cultures treated with the respiration inhibitor NaN3). Conversely, when the rates of energy production prevail over the rates of energy consumption, a build-up of ATP stimulates negative feedbacks (for example, through ATP-dependent stimulation of pyruvate dehydrogenase kinase (Roche and Hiromasa, 2007)) resulting in downregulation of the
energy metabolism in the continuous presence of metabolic substrates. It is conceivable that during differentiation, a gradual increase in energy consumption provides tolerance room for an increase in energy production, so that moderate excess of energy substrates, such as pyruvate, may facilitate the realization of differentiation signaling. This logic also accounts for a bell-shaped dose-dependence of osteoclastogenesis on concentration of pyruvate.

The addition of pyruvate during osteoclastogenesis augmented cell energy metabolism, evident from an increase in medium acidification, mitochondrial activity and ATP production. Together with previous studies (Dudley and Spiro, 1961; Williams et al., 1997; Kim et al., 2007; Ishii et al., 2009; Le Nihouannen et al., 2010), these data demonstrate that osteoclast differentiation is an energy-expensive process, which requires strong upregulation of energy metabolism. Pyruvate was previously shown to protect cells from apoptosis induced by oxidative stress (Long and Halliwell, 2009). We have also observed an anti-apoptotic effect of pyruvate; however, the osteoclast redox state was affected minimally. Moreover, it was previously shown that oxidative stress supports osteoclast differentiation (Huh et al., 2006; Le Nihouannen et al., 2010), therefore the potential anti-oxidative effects of pyruvate are likely counter-productive during osteoclastogenesis. Thus, our data suggest that osteoclastogenic action of pyruvate is due to its effect on energy metabolism.

We assessed the roles of metabolic sensor AMPK in pyruvate-induced osteoclastogenesis. AMPK is directly linked to energy metabolism reflected by AMP/ATP ratio, and its activation leads to energy conservation through inhibition of cell growth, lipogenesis and protein biosynthesis (Gwinn et al., 2008; Lage et al., 2008). Inhibition of AMPK was required for osteoclast growth observed in energy-rich conditions, while activation of AMPK prevented pyruvate-induced increase in cell size. Previous report demonstrated that AMPK activator, AICAR, decreases osteoclast activity in vitro and in vivo through AMPK-dependent pathways (Quinn et al., 2010). It is known that larger osteoclasts are associated with higher resorptive activity (Trebec et al., 2007), therefore these effects may reflect decreased osteoclast size following treatment with AICAR.

Taken together, our data demonstrate the existence of reciprocal communication between the cell energy metabolism and the differentiation signaling resulting in formation of osteoclasts, cells responsible for bone destruction. These studies are important for understanding the mechanisms underlying skeletal disorders associated with diseases resulting in abnormal levels of energy metabolism substrates, such as diabetes mellitus (Nicoledus and Folsom, 2001; Kayal et al., 2007; Khazai et al., 2009) and pyruvate dehydrogenase complex deficiencies (Barnerias et al., 2010), as well as for understanding the general relationship between homeostatic and functional cellular operations.

Materials and Methods

Cell culture reagents

Fetal bovine serum (FBS) was from HyClone (SH 30396-03), MEM (11095), α-MEM (310-022-CL), DMEM (319-020-CL), pyruvate (600-110-EL), L-glutamine (609-065-EL), penicillin/streptomycin (450-201-EL), trypsin/ethylenediamine tetraacetic acid (T/E; 325-042-EL) were from Wisent Inc. L-ascorbic acid (A5960), and Sodium azide (S2002) were from Sigma–Aldrich Co. Dorsomorphin 2HCl (3093) and AICAR (2840) were from TOCRIS bioscience. Recombinant human M-CSF (300-25) was from Peprotech Inc. Recombinant glutathione S-transferase-soluble RANKL was purified from the clones kindly provided by Dr M.F. Manolson (University of Toronto).

In vivo study

All animal studies were performed in accordance with the McGill University animal care guidelines established by the Canadian Council on Animal Care. Six-week-old C57BL6/J mice (Charles River) received 0.75 g/kg/day of pyruvate solution or sterile saline by daily i.p. injections for 6 days. On day 7, 24 hours after the last injection, blood samples were collected and the long bones were isolated. Six-hour fasted blood levels of glucose and pyruvate were evaluated using an Accu-chek Aviva glucometer and EnzymeChrom™ Pyruvate Assay Kit (BioAssay Systems, EPYR-100). Bone samples were embedded in paraffin and 5 μm sections were stained for tartrate-resistant acid phosphatase (TRAP). Osteoclast analysis in bone sections was conducted using Osteomeasure software (Osteometrics Inc., Atlanta GA).

Osteoclast cultures from mouse bone marrow cells

Mouse bone marrow cells were collected from six-week-old C57BL6/J mice (Charles River) for total bone marrow cultures or BALB/c mice (Charles River) for non-adherent bone marrow cultures as described previously (Tiedemann et al., 2009). For total bone marrow cultures, cells were plated at a density of 2.5×10⁹ cells/cm² and cultured in MEM supplemented with 1% penicillin-streptomycin and 10% FBS in the presence of RANKL (50 ng/ml) and AA (50 μg/ml). For non-adherent bone marrow cultures, cells were first cultured in 75 cm² tissue culture flasks (15×10⁶ cells per flask) with M-CSF (25 ng/ml). On day 1, non-adherent cells were removed, resuspended in 8 cm² MEM with M-CSF (50 ng/ml) and RANKL (100 ng/ml), and plated at 7×10⁶ cells/cm². Medium was changed every second day.

RAW 264.7 monocyte cell culture

RAW 264.7 cells (ATCC) were cultured in 25 cm² tissue culture flasks in DMEM supplemented with 1% penicillin-streptomycin and 10% FBS. To generate osteoclasts, RAW 264.7 cells were plated at 10⁶ cells/cm². On days 1 and 3, medium was changed and RANKL (50 ng/ml) was added.

Characterization of osteoclasts

Cell cultures were fixed using 4% paraformaldehyde and stained for TRAP (Sigma–Aldrich Co., 387A). Osteoclasts were identified as multinucleated (more than 3 nuclei) TRAP-positive cells and were further characterized by image analysis using PixeLINK Capture SE® software (PixeLINK) and Image J. For each experimental condition, the cell surface area and nuclei number of ~100 osteoclasts were evaluated. For confocal microscopy, live osteoclasts generated from RAW 264.7 cells on glass coverslips were incubated with the fluorescent lipophilic membrane probe Dil (3 μM, Vybrant® Di, Invitrogen®; V-22885), and visualized with LSM510 confocal microscope (Carl Zeiss Inc.). Images of at least 20 fields/condition were used to evaluate osteoclast height.

Cell proliferation assay

RAW 264.7 cells cultured for 24 hours in 96-well flat bottom plates were supplemented with indicated additions, and cultured for 48 hours. Proliferation assay was performed using the BrdU CHEMICON® Cell Proliferation Assay Kit (Millipore, 2750) and a microplate reader (Beckman Coulter AD340, Beckman Coulter Inc.).

Apoptosis assay

RAW 264.7 cells plated on glass coverslips, were treated as indicated, fixed and stained using DAPI dihydrochloride (InvitrogenTM, D1306). Ten random images per condition were collected, the background fluorescence in red and green channel was subtracted from the

Mitochondrial activity

RAW 264.7 cells were plated on 10 mm diameter glass coverslips. Mitochondrial activity was assessed using 5,5′,6,6′-tetrachloro-1,1′,3′,3′-tetraethylbenzimidazolylcarboxyanine iodide (JC-1; BIC233), Invitrogen®; T-3168) as described previously (Komarova et al., 2000). In each experiment, images of at least 9 fields were collected, the background fluorescence in red and green channel was subtracted from the
Energetics in osteoclastogenesis

Protein extraction and immunoblotting

Cell lysates were extracted in RIPA lysis buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 mM mg/μl aprotinin, 2 mg/ml leupeptin, 0.1 mM phenylmethysulfonyl fluoride, 20 mM sodium fluoride, 0.5 mM sodium orthovanadate and centrifuged at 12,000 g for 10 minutes at 4°C. Supernatant was collected, and protein was measured using a Quant-iTTM protein assay kit (Invitrogen). Protein extraction and immunoblotting were performed using an ATP Determination Kit (InvitrogenTM, A22066) and a luminometer (FemtoTurnTM, Zylux Corp.). GSHt and GSSG were measured using a GSH-GSSG Assay Kit (Oxford Biomedical ResearchTM, GT35) and microplate reader (Tecan’s Infinite® F200). ATP and GSHt concentrations were normalized to the protein content measured using a Quant-iTTM protein assay kit (Invitrogen).

Statistical analysis

Data are presented as representative images, representative experiments or as means ± standard error of the mean, with n indicating the number of independent experiments. Differences were assessed by ANOVA for correlated samples followed by Tukey post-test, Student t-test, or paired Student t-test as indicated in the figure legends and accepted as statistically significant at P<0.05.

Acknowledgements

We thank Dr. M.F. Manolson, University of Toronto for providing reagents used in this study and Xiaomin Yu for her help in acquisition of preliminary data. This study was supported by the Canadian Institute for Health Research. D.L.N. was supported by the CIHR Training Program in Skeletal Health Research, the Canadian Arthritis Network and les Fonds de la Recherche en Santé du Québec. J.E.F. was supported by the CIHR Training Program in Skeletal Health Research and McGill University. J.E.B. holds Canada Research Chair in Osteointegrative Biomaterials and S.V.K. holds Canada Research Chair in Osteoclast Biology.

Competing Interests

The authors have no competing interests to declare.

References


siRNA against AMPKα1 and AMPKγ1

Short interfering RNAs for AMPKα1 (5’-GGAUUGCUUAUGACCCUAUAGAT-3’ and 5’-ACUCUAUAGGCUAGUAUGCUAACG-3’), (5’-GGAGAACGCAACAGAAAACAAA-3’) and 5’-AACGAGCUAGUAAUGCUUAGC-3’; and 5’-AUCGGAGAGGCGACGAGGCGG-3’; (5’-AGAGCCAGGAAAGCAGGCGG-3’ and 5’-ACUUGCAAGCAGACAGUACCUUC-3’), (5’-AGCGGAACAUAAUGCUUCGUAGC-3’) and 5’-AUCUGUUAGGACAGGCGG-3’; (5’-AUGCUAAUGUAGGAGGAAGG-3’) and 5’-AGCAAGGAAGCAGGCGG-3’; and 5’-AGGAACACAAAAAGACAAA-3’ and 5’-AAAUUUAACAAACAAAGAGGCCC-3’, (5’-AGGCAACCAAAUUAGGAGG-3’ and 5’-AAUACAGUAAAUAAACAGCAG-3’) were purchased from Integrated DNA Technologies (IDT). siRNA interference duplex (5’-GCGACAGUCAUGUGAAGAATT-3’) and negative control double scrambled RNA interference duplex (5’-CGUAAGCAGCUAAUUAUGCCGC-3’ and 5’-AAGGUGACAAACAGGACACG-3’) were purchased from Integrated DNA Technologies (IDT). siRNA interference duplex (5’-GCGACAGUCAUGUGAAGAATT-3’) and negative control double scrambled RNA interference duplex (5’-CGUAAGCAGCUAAUUAUGCCGC-3’ and 5’-AAGGUGACAAACAGGACACG-3’) were purchased from Integrated DNA Technologies (IDT). siRNA interference duplex (5’-GCGACAGUCAUGUGAAGAATT-3’) and negative control double scrambled RNA interference duplex (5’-CGUAAGCAGCUAAUUAUGCCGC-3’ and 5’-AAGGUGACAAACAGGACACG-3’).


